Mariana Coelho

Mariana Coelho

Auto-generated profile, based on publicly available information

Mariana Coelho

Division of Molecular Genetics German Cancer Research Center (DKFZ) Heidelberg Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2024 in Blood
Verified
Journal Article
Closed access
PDF file
BBBerit J. Brinkmann
Berit J. Brinkmann
AFAlessia Floerchinger
Alessia Floerchinger
CSChristina Schniederjohann
Christina Schniederjohann
TRTobias Roider
Tobias Roider
MCMariana Coelho
Mariana Coelho
SDSascha Dietrich
Sascha Dietrich
Relapse after anti-CD19 chimeric antigen receptor (CD19-CAR) occurs in a substantial proportion of patients with lymphoid malignancies. We assessed the potential benefits of co-administering CD20-targeting bispecific antibodies (CD20-BsAbs) with CD19-CAR T cells with the aim of enhancing immunotherapeutic efficacy. Addition of CD20-BsAbs to cocultures of CD19-CARs and primary samples of B-cell malignancies, comprising malignant B cells and endogenous T cells, significantly improved killing of malignant cells and enhanced the expansion of both endogenous T cells and CD19-CAR T cells. In an immunocompetent mouse model of chronic lymphocytic leukemia, relapse after initial treatment response frequently occurred after CD19-CAR T-cell monotherapy. Additional treatment with CD20-BsAbs significantly enhanced the treatment response and led to improved eradication of malignant cells. Higher efficacy was accompanied by improved T-cell expansion with CD20-BsAb administration and led to longer survival with 80% of the mice being cured with no detectable malignant cell population within 8 weeks of therapy initiation. Collectively, our in vitro and in vivo data demonstrate enhanced therapeutic efficacy of CD19-CAR T cells when combined with CD20-BsAbs in B-cell malignancies. Activation and proliferation of both infused CAR T cells and endogenous T cells may contribute to improved disease control.

1 August 2024 in Blood
Verified
Journal Article
Closed access
PDF file
PRPhilipp M. Roessner
Philipp M. Roessner
ISIsabelle Seufert
Isabelle Seufert
VCVicente Chapaprieta
Vicente Chapaprieta
RJRuparoshni Jayabalan
Ruparoshni Jayabalan
HBHannah Briesch
Hannah Briesch
MSMartina Seiffert
Martina Seiffert
The T-box transcription factor T-bet is known as a master regulator of the T-cell response but its role in malignant B cells has not been sufficiently explored. Here, we conducted single-cell resolved multi-omics analyses of malignant B cells from patients with chronic lymphocytic leukemia (CLL) and studied a CLL mouse model with a genetic knockout of Tbx21. We found that T-bet acts as a tumor suppressor in malignant B cells by decreasing their proliferation rate. NF-κB activity, induced by inflammatory signals provided by the microenvironment, triggered T-bet expression, which affected promoter-proximal and distal chromatin coaccessibility and controlled a specific gene signature by mainly suppressing transcription. Gene set enrichment analysis identified a positive regulation of interferon signaling and negative control of proliferation by T-bet. In line, we showed that T-bet represses cell cycling and is associated with longer overall survival of patients with CLL. Our study uncovered a novel tumor suppressive role of T-bet in malignant B cells via its regulation of inflammatory processes and cell cycling, which has implications for the stratification and therapy of patients with CLL. Linking T-bet activity to inflammation explains the good prognostic role of genetic alterations in the inflammatory signaling pathways in CLL.

1 December 2010 in Psychologica
Verified
Journal Article
Open access
JMJorge Simões Martins
Jorge Simões Martins
MCMariana Serra Coelho
Mariana Serra Coelho
JFJoaquim Armando Gomes Alves A Ferreira
Joaquim Armando Gomes Alves A Ferreira

14 September 2026 in HemaSphere
Verified
Journal Article
Open access
PDF file
HBHannah Briesch
Hannah Briesch
MCMariana Coelho
Mariana Coelho
AFAlessia Floerchinger
Alessia Floerchinger
YBYuliia Borysovych
Yuliia Borysovych
NANicolas Aubert
Nicolas Aubert
MSMartina Seiffert
Martina Seiffert
Chronic lymphocytic leukemia (CLL) exhibits marked clinical heterogeneity that cannot be fully explained by genetic alterations, underscoring the critical role of the tumor microenvironment in disease progression and therapeutic resistance. To delineate the temporal evolution of immune dysregulation in CLL, we used the Eµ‐TCL1 adoptive transfer (TCL1‐AT) mouse model combined with high‐dimensional spectral flow cytometry to longitudinally profile lymphoid and myeloid compartments. To assess the reproducibility across different disease kinetics, we analyzed seven independent TCL1‐AT cohorts generated from distinct primary tumors. CLL progression was associated with coordinated restructuring of adaptive and innate immune cell populations. Within the T‐cell compartment, early activation and effector expansion transitioned to a progressive accumulation of terminally exhausted CD8 + T cells. Concurrently, immunoregulatory populations expanded, including regulatory type 1 (Tr1)‐like CD4 + T cells, activated regulatory T cells (Tregs) and, importantly, a previously underappreciated Eomes‐expressing Treg subset. Natural killer (NK) cells exhibited transient expansion followed by differentiation and acquisition of exhaustion markers. Myeloid cell profiling revealed an expansion of immunosuppressive PD‐L1 high patrolling monocytes, mature regulatory dendritic cells (mregDCs), and phenotypic reprogramming of dendritic cells (DCs) consistent with impaired antigen presentation and promotion of T‐cell exhaustion and regulatory T‐cell subsets. Despite substantial variation in leukemia kinetics, expansion of patrolling monocytes, exhausted CD8 + T cells, and Tregs was consistently observed across all seven independent TCL1‐AT cohorts, demonstrating robust immune remodeling. Collectively, our findings demonstrate a stepwise transition toward a suppressive microenvironment involving innate and adaptive immune compartments in the Eµ‐TCL1 mouse model, providing a framework for understanding immune failure in CLL and informing strategies to restore anti‐leukemic immunity.